Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 93.2%

Neg 0% Neu 0% Pos 93.2%

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.